Your body is accumulating zombie cells right now. Formally called senescent cells, these are cells that have stopped dividing but refuse to die. They linger in tissues, secreting a toxic cocktail of inflammatory molecules known as the senescence-associated secretory phenotype (SASP). In small numbers, senescence is protective -- it prevents damaged cells from becoming cancerous. But as we age, senescent cells accumulate, and their SASP drives chronic inflammation, tissue dysfunction, and accelerated aging.
The idea behind senolytics is simple and compelling: develop compounds that selectively kill senescent cells while leaving healthy cells intact. Clear the zombies, reduce inflammation, restore tissue function. In animal models, this concept has produced some of the most dramatic results in aging research. The question is whether it translates to humans -- and whether you can do it yourself with supplements.
The animal data: genuinely impressive
The senolytic field was launched by a landmark 2015 paper from James Kirkland and Tamara Tchkonia at the Mayo Clinic. They demonstrated that the combination of dasatinib (a cancer drug) and quercetin (a plant flavonoid) selectively cleared senescent cells in aged mice, improving physical function, extending healthspan, and even increasing lifespan by approximately 36% when treatment started in very old mice (equivalent to roughly 75-80 in human years).
Subsequent mouse studies have been remarkable. Senolytic treatment has improved cardiac function, reduced pulmonary fibrosis, enhanced insulin sensitivity, improved bone density, reduced neuroinflammation, and even improved cognitive function in aged animals. A 2018 study showed that transplanting just a small number of senescent cells into young mice caused persistent physical dysfunction -- and that senolytics reversed it.
Fisetin, a flavonoid found in strawberries, entered the picture when a 2018 screen by Yousefzadeh et al. at the University of Minnesota identified it as a potent senolytic with a favorable safety profile in mice. At high doses, fisetin reduced senescent cell burden and extended median lifespan in aged mice by approximately 10%.
The human trials: early but underway
The Mayo Clinic group has led the translation effort. A 2019 pilot study (Justice et al., EBioMedicine) tested dasatinib (100mg) plus quercetin (1,000mg) in 14 patients with idiopathic pulmonary fibrosis over 3 weeks (3 doses per week). The treatment improved 6-minute walk distance and other physical function measures. This was a small, open-label study -- encouraging but far from definitive.
The AFFIRM-LITE trial, a larger randomized controlled study testing intermittent dasatinib + quercetin in age-related kidney decline, has reported interim results showing reductions in senescent cell markers and inflammatory biomarkers. Full results are expected in 2026.
For fisetin specifically, the AFFIRM trial at the Mayo Clinic began enrolling participants to test high-dose fisetin (20 mg/kg for 2 consecutive days monthly) in older adults. Preliminary safety data showed the protocol was well-tolerated, but efficacy data is still maturing.
The honest assessment: human senolytic research is in its early clinical phase. There are positive signals, but we do not yet have large, long-term RCTs confirming that senolytics extend healthspan or lifespan in humans.
Why you cannot just take quercetin daily
This is a critical point that the supplement industry largely ignores. Senolytics work through a "hit-and-run" mechanism. You take a high dose intermittently to trigger apoptosis (programmed cell death) in senescent cells, then stop to allow the body to clear the debris and recover.
Taking quercetin daily at typical supplement doses (500-1,000 mg) does NOT function as a senolytic. At these doses and frequencies, quercetin acts primarily as an anti-inflammatory and antioxidant -- useful properties, but fundamentally different from senolytic cell clearance. The senolytic effect requires higher doses delivered in short, intermittent bursts.
The Kirkland protocol uses quercetin at 1,000 mg combined with dasatinib 100 mg, taken for just 3 consecutive days, then off for several weeks. The fisetin protocol uses approximately 20 mg/kg (roughly 1,400 mg for a 70 kg person) for 2 consecutive days per month.
If you are buying quercetin and taking 500 mg daily hoping for senolytic benefits, you are getting an anti-inflammatory supplement -- not a senolytic intervention. The cycling matters enormously.
Dasatinib + Quercetin: the problem with the "D+Q" protocol
Dasatinib is a prescription tyrosine kinase inhibitor approved for chronic myeloid leukemia. It is not a supplement. It carries real side effects including pleural effusion, myelosuppression, and QT prolongation. Using it off-label for longevity without medical supervision is genuinely dangerous.
Some longevity enthusiasts obtain dasatinib through gray-market sources or sympathetic physicians. This is the Wild West of longevity medicine, and the risk-benefit calculation is very different from taking a quercetin supplement. The D+Q protocol should only be considered under direct physician supervision, and even then, the evidence base in healthy aging adults is limited.
Quercetin alone (at senolytic doses, intermittently) is a more accessible option with a better safety profile, though its senolytic potency without dasatinib is substantially lower. Fisetin may represent a better standalone option based on the mouse data.
Fisetin: the most accessible senolytic candidate
Fisetin has generated the most interest among supplement users because it showed senolytic activity in mice without requiring a prescription drug partner. The practical challenges: fisetin has poor bioavailability (approximately 5-10% oral absorption), and the effective senolytic dose in mice (approximately 100 mg/kg) translates to very high human doses.
Most fisetin supplements are sold at 100-500 mg doses for daily use. Again, this is below the threshold for senolytic activity and defaults to antioxidant/anti-inflammatory effects. Those pursuing fisetin as a senolytic typically follow protocols of 1,000-2,000 mg for 2 consecutive days monthly, though this is extrapolated from animal data, not validated in human RCTs.
Newer liposomal fisetin formulations claim improved bioavailability, but comparative senolytic efficacy data in humans does not yet exist.
Safety concerns
Intermittent high-dose flavonoid protocols have theoretical risks. Quercetin at high doses can inhibit CYP3A4 and CYP2C9 enzymes, affecting drug metabolism. Fisetin at high doses may have anti-platelet effects. Neither compound has been tested in long-term cycling protocols in large human populations.
There is also a theoretical concern: senescent cells play protective roles in wound healing, tissue repair, and tumor suppression. Aggressive senolytic clearance could potentially impair these functions, though animal studies have not shown this to be a major problem at the cycling frequencies studied.
What is proven vs. what is speculated
Proven in animals: Senolytics can clear senescent cells, reduce SASP, improve physical function, and extend lifespan in mice. Multiple independent labs have replicated these findings.
Supported by early human data: D+Q can reduce senescent cell markers in humans and may improve physical function in specific disease contexts. High-dose fisetin appears safe in short-term human use.
Speculated: That supplement-available senolytics at practical doses meaningfully extend human healthspan or lifespan. That self-directed senolytic protocols are safe long-term. That monthly fisetin cycling provides the same benefits seen in mouse studies.
Our take
Senolytics represent one of the most exciting frontiers in aging research. The science is real, the animal data is compelling, and the clinical pipeline is active. However, the gap between mouse lifespan studies and validated human protocols is enormous.
If you are interested in senolytics, the most evidence-aligned approach would be: (1) standard daily quercetin or fisetin at anti-inflammatory doses for general health benefits, while (2) watching the clinical trial results closely before committing to aggressive senolytic cycling protocols. The Mayo Clinic trials will be pivotal.
Do not let the excitement of the science lead you to treat unvalidated protocols as proven interventions. This field is moving fast, and the best answer in 2027 may be very different from today's.